China–Africa and China–Asia Collaboration on Schistosomiasis Control

Impact evaluation of schistosomiasis control into elimination interventions models in P. R. China and Africa

“…Estimated 200 million cases of 600 million people at high risk of schistosoma species in 76 countries, it is a significant public health problem, concentrated in sub-Saharan Africa, South East Asia and South America according to World Health Organization [1,3,7]. Repeated and periodic mass chemotherapy administration of antihelmenthic drugs mainly Praziquantel (PZQ) has been the backbone in most national and global schistosomiasis prevention and control programs that have averted millions of deaths in risk and affected populations in these endemic settings [1,3].…”

“…With appropriate and increased political commitment and investment, the strategic China national schistosomiasis elimination strategy has be launched with major goal of elimination of the diseases from 2016-2025 aiming at establishing reliable and operational approaches at interrupting transmission in more than 90% and elimination in 75% and 90% of the endemic counties by 2020 and 2025 respectively [2,3]. Hence, achieving the vision and goal set of China nationwide schistosomiasis free beyond 2025 requires scale up of innovative and integrated functional surveillance-response system interventions.…”

“…China and Africa [1,3,5,8]. However, existing national control models and strategies may not eliminate the diseases except if innovative, concerted and programmatic strategies developed and used at the same level of intensity at all levels [10,11].…”

“…Estimated 200 million cases of 600 million people at high risk of schistosoma species in 76 countries, it is a significant public health problem, concentrated in sub-Saharan Africa, South East Asia and South America according to World Health Organization [1,3,7]. Repeated and periodic mass chemotherapy administration of antihelmenthic drugs mainly Praziquantel (PZQ) has been the backbone in most national and global schistosomiasis prevention and control programs that have averted millions of deaths in risk and affected populations in these endemic settings [1,3]. For example in 1987, the first systematic mapping that resulted in the global distribution of schistosomiasis Atlas underscored the urgent need for more effective, contextual and inexpensive epidemiological surveillance evaluation in identifying mass chemotherapy in high-risk communities [7][8][9].…”

“…Schistosomiasis or bilharziasis is one of infectious disease of poverty, characterized by severe morbidity and disability that worsens poverty and inequity in vulnerable children in remote settings and resource-limited minority population [2]. Schistosomiasis urogenital and intestinal are responsible the major public health burden and caused by Schistosoma haematobium and S. mansoni versus S. [1,3,4]. S. haematobium and S. mansoni are found widespread in most endemic countries in Africa, leading to the persistent prevalence of the two common forms of urinogenital and intestinal schistosomiasis [5,6], while S. japonicum and S. mekongi are mainly intestinal forms in South-East China [5].…”